By: IPP Bureau
Last updated : November 08, 2022 10:45 am
The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI)
Zydus Lifesciences Ltd., an innovation driven global life sciences company announced the receipt of an Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its formulations manufacturing facility in Moraiya, near Ahmedabad.
The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI). The USFDA had inspected the facility from 26th July - 5th August, 2022 and concluded with four observations. The USFDA has indicated that the inspection is closed.
Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.
The group employs over 23,000 people worldwide and is driven by its mission to unlock new possibilities in life sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through path-breaking discoveries.